Skip to content
OpenCapital
Get started

Bicara Therapeutics BCAX Share-based compensation expense related to employee stock plans

Share-based compensation expense related to employee stock plans at other companies

Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
——

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K—
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.68B+81.4%

Returns & leverage

See full
Return on equity-32.3%—
Debt / equity0×0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's share-based compensation expense related to employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's share-based compensation expense related to employee stock plans?
Bicara Therapeutics (BCAX) reported share-based compensation expense related to employee stock plans of $5.86M in Q1 2026.
How has Bicara Therapeutics's share-based compensation expense related to employee stock plans changed year-over-year?
Bicara Therapeutics's share-based compensation expense related to employee stock plans increased by 69.7% year-over-year, from $3.45M to $5.86M.